Edition:
United Kingdom

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Global Select Market

64.20USD
2:39pm GMT
Change (% chg)

$0.06 (+0.09%)
Prev Close
$64.14
Open
$64.19
Day's High
$64.71
Day's Low
$63.04
Volume
21,576
Avg. Vol
244,942
52-wk High
$67.03
52-wk Low
$24.65

Latest Key Developments (Source: Significant Developments)

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Thursday, 17 Jan 2019 

Jan 16 (Reuters) - Mirati Therapeutics Inc ::MIRATI THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.MIRATI THERAPEUTICS- ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.6 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $62.00 PER SHARE.  Full Article

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
Wednesday, 16 Jan 2019 

Mirati Therapeutics Inc ::MIRATI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.MIRATI THERAPEUTICS INC - IT INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, $75.0 MILLION OF SHARES OF ITS COMMON STOCK.MIRATI THERAPEUTICS INC - ALL OF SHARES ARE BEING OFFERED BY MIRATI.  Full Article

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For Planned Phase 3 Trial To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Bristol-Myers Squibb Co ::MIRATI ANNOUNCES CLINICAL COLLABORATION WITH BRISTOL-MYERS SQUIBB FOR THE PLANNED PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER TO EVALUATE SITRAVATINIB IN COMBINATION WITH NIVOLUMAB (OPDIVO®).MIRATI THERAPEUTICS INC - PHASE 3 PIVOTAL TRIAL IS EXPECTED TO START IN FIRST HALF OF 2019.MIRATI THERAPEUTICS INC - UNDER TERMS OF COLLABORATION, MIRATI WILL SPONSOR AND FUND CLINICAL TRIAL.MIRATI THERAPEUTICS INC - UNDER TERMS OF COLLABORATION BRISTOL-MYERS SQUIBB WILL PROVIDE NIVOLUMAB AT NO COST.  Full Article

Mirati Therapeutics Inc Files For Potential Mixed Shelf Offering
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Mirati Therapeutics Inc ::MIRATI THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING.  Full Article

Mirati Therapeutics Prices 2.75 Mln Shares Of Its Common Stock At A Price Of $38.85
Thursday, 7 Jun 2018 

June 7 (Reuters) - Mirati Therapeutics Inc ::MIRATI THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 2.75 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $38.85 PER SHARE.  Full Article

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Mirati Therapeutics Inc ::MIRATI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Mirati Therapeutics Reports Q1 Loss Per Share $0.51
Monday, 7 May 2018 

May 7 (Reuters) - Mirati Therapeutics Inc ::MIRATI THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.51.Q1 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE $9.5 MILLION.ON TRACK TO FILE PLANNED INDA FOR MRTX849, A POTENT AND SELECTIVE INHIBITOR FOR KRAS, IN Q4 OF 2018.  Full Article

Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Beigene Ltd ::BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION.BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD..BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE.BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS.BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATI'S SITRAVATINIB IN ASIA.  Full Article

Mirati prices public offering of 2 mln shares at $13 per share​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Mirati Therapeutics Inc -:Mirati Therapeutics announces pricing of public offering of common stock.Mirati Therapeutics Inc - ‍pricing of underwritten public offering of 2 million shares of its common stock at a price to public of $13.00 per share​.  Full Article

Mirati announces advancement of opportunities with inhibitor programs
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Mirati Therapeutics Inc ::Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs.Mirati Therapeutics - ‍"reprioritizing" development programs to capitalize on data and development opportunities in its sitravatinib and kras programs​.Mirati Therapeutics - ‍reallocation of resources to support expansion of sitravatinib and kras programs, is expected to fund operations into late 2019​.  Full Article